- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 549359, 10 pages
Molecular Imaging of Nonsmall Cell Lung Carcinomas Expressing Active Mutant EGFR Kinase Using PET with [124I]-Morpholino-IPQA
1National PET/Cyclotron Center, Department of Nuclear Medicine, Taipei Veterans General Hospital, Taiwan
2Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, Taipei, Taiwan
3Biophotonic and Molecular Imaging Research Center, National Yang-Ming University, Taipei, Taiwan
4Taiwan Mouse Clinic, National Comprehensive Mouse Phenotyping and Drug Testing Center, Taiwan
5Department of Experimental Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, TX, USA
6Department of Medicinal Imaging and Radiological Sciences, College of Health Sciences, Kaohsiung Medical University, Kaohsiung, Taiwan
7Department of Biomedical Engineering, Wayne State University, MI, USA
8Department of Nuclear Medicine, National Yang-Ming University School of Medicine, Taiwan
Received 25 April 2013; Revised 11 June 2013; Accepted 14 June 2013
Academic Editor: Shaoli Song
Copyright © 2013 Skye Hsin-Hsien Yeh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- ACS, 2012, http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-key-statistics.
- H. A. Burris III, “Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs,” Oncogene, vol. 28, no. 1, pp. S4–S13, 2009.
- Y. Yarden, “The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities,” European Journal of Cancer, vol. 37, no. 4, pp. S3–S8, 2001.
- A. F. Gazdar, “Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors,” Oncogene, vol. 28, no. 1, pp. S24–S31, 2009.
- S. V. Sharma, D. W. Bell, J. Settleman, and D. A. Haber, “Epidermal growth factor receptor mutations in lung cancer,” Nature Reviews Cancer, vol. 7, no. 3, pp. 169–181, 2007.
- C. A. Reade and A. K. Ganti, “EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab,” Biologics, vol. 3, pp. 215–224, 2009.
- F. Fukuoka, “Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial),” Journal of Clinical Oncology, vol. 21, no. 12, pp. 2237–2246, 2003.
- M. G. Kris, R. B. Natale, R. S. Herbst et al., “Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial,” Journal of the American Medical Association, vol. 290, no. 16, pp. 2149–2158, 2003.
- J. G. Paez, P. A. Jänne, J. C. Lee et al., “EGFR mutations in lung, cancer: correlation with clinical response to gefitinib therapy,” Science, vol. 304, no. 5676, pp. 1497–1500, 2004.
- S.-F. Huang, H.-P. Liu, L.-H. Li et al., “High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan,” Clinical Cancer Research, vol. 10, no. 24, pp. 8195–8203, 2004.
- N. Thatcher, A. Chang, P. Parikh et al., “Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer),” The Lancet, vol. 366, no. 9496, pp. 1527–1537, 2005.
- F. A. Shepherd and M.-S. Tsao, “Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy,” Journal of Clinical Oncology, vol. 24, no. 7, pp. 1219–1220, 2006.
- G. J. Riely, W. Pao, D. Pham et al., “Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib,” Clinical Cancer Research, vol. 12, no. 3, part 1, pp. 839–844, 2006.
- T. J. Lynch, D. W. Bell, R. Sordella et al., “Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib,” The New England Journal of Medicine, vol. 350, no. 21, pp. 2129–2139, 2004.
- W. Pao, V. A. Miller, K. A. Politi et al., “Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain,” PLoS Medicine, vol. 2, no. 3, article e73, 2005.
- D. M. Jackman, B. Y. Yeap, L. V. Sequist et al., “Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib,” Clinical Cancer Research, vol. 12, no. 13, pp. 3908–3914, 2006.
- G. J. Riely, K. A. Politi, V. A. Miller, and W. Pao, “Update on epidermal growth factor receptor mutations in non-small cell lung cancer,” Clinical Cancer Research, vol. 12, no. 24, pp. 7232–7241, 2006.
- G. Giaccone, “Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 23, no. 14, pp. 3235–3242, 2005.
- P. A. Jänne, “Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations,” Seminars in Oncology, vol. 32, no. 6, supplement 10, pp. S9–e15, 2005.
- J. G. Gelovani, “Molecular imaging of epidermal growth factor receptor expression-activity at the kinase level in tumors with positron emission tomography,” Cancer and Metastasis Reviews, vol. 27, no. 4, pp. 645–653, 2008.
- S. Dissoki, Y. Aviv, D. Laky, G. Abourbeh, A. Levitzki, and E. Mishani, “The effect of the [18F]-PEG group on tracer qualification of [4-(phenylamino)-quinazoline-6-YL]-amide moiety-An EGFR putative irreversible inhibitor,” Applied Radiation and Isotopes, vol. 65, no. 10, pp. 1140–1151, 2007.
- E. Mishani, G. Abourbeh, Y. Rozen et al., “Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: potential PET bioprobes for molecular imaging of EGFR-positive tumors,” Nuclear Medicine and Biology, vol. 31, no. 4, pp. 469–476, 2004.
- E. Mishani and G. Abourbeh, “Cancer molecular imaging: radionuclide-based biomarkers of the epidermal growth factor receptor (EGFR),” Current Topics in Medicinal Chemistry, vol. 7, no. 18, pp. 1755–1772, 2007.
- E. Mishani and A. Hagooly, “Strategies for molecular imaging of epidermal growth factor receptor tyrosine kinase in cancer,” Journal of Nuclear Medicine, vol. 50, no. 8, pp. 1199–1202, 2009.
- T. A. Bonasera, G. Ortu, Y. Rozen et al., “Potential18F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase,” Nuclear Medicine and Biology, vol. 28, no. 4, pp. 359–374, 2001.
- G. Ortu, I. Ben-David, Y. Rozen et al., “Labeled EGFr-TK irreversible inhibitor (ML03): in vitro and in vivo properties, potential as pet biomarker for cancer and feasibility as anticancer drug,” International Journal of Cancer, vol. 101, no. 4, pp. 360–370, 2002.
- G. Abourbeh, S. Dissoki, O. Jacobson et al., “Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors,” Nuclear Medicine and Biology, vol. 34, no. 1, pp. 55–70, 2007.
- A. Pal, A. Glekas, M. Doubrovin et al., “Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography,” Molecular Imaging and Biology, vol. 8, no. 5, pp. 262–277, 2006.
- H. Su, Y. Seimbille, G. Z. Ferl et al., “Evaluation of [18F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 6, pp. 1089–1099, 2008.
- H. Wang, J.-M. Yu, G.-R. Yang et al., “Further characterization of the epidermal growth factor receptor ligand 11C-PD153035,” Chinese Medical Journal, vol. 120, no. 11, pp. 960–964, 2007.
- A. A. Memon, S. Jakobsen, F. Dagnaes-Hansen, B. S. Sorensen, S. Keiding, and E. Nexo, “Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts,” Cancer Research, vol. 69, no. 3, pp. 873–878, 2009.
- N. Liu, M. Li, X. Li et al., “PET-based biodistribution and radiation dosimetry of epidermal growth factor receptor-selective tracer 11C-PD153035 in humans,” Journal of Nuclear Medicine, vol. 50, no. 2, pp. 303–308, 2009.
- W.-P. Deng, W. K. Yang, W.-F. Lai et al., “Non-invasive in vivo imaging with radiolabelled FIAU for monitoring cancer gene therapy using herpes simplex virus type 1 thymidine kinase and ganciclovir,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 31, no. 1, pp. 99–109, 2004.
- A. Fredriksson, P. Johnström, J.-O. Thorell et al., “In vivo evaluation of the biodistribution of 11C-labeled PD153035 in rats without and with neuroblastoma implants,” Life Sciences, vol. 65, no. 2, pp. 165–174, 1999.
- M. Shaul, G. Abourbeh, O. Jacobson et al., “Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer,” Bioorganic and Medicinal Chemistry, vol. 12, no. 13, pp. 3421–3429, 2004.
- A. Mohammed, N. B. Janakiram, Q. Li et al., “The epidermal growth factor receptor inhibitor gefitinib prevents the progression of pancreatic lesions to carcinoma in a conditional LSL- transgenic mouse model,” Cancer Prevention Research, vol. 3, no. 11, pp. 1417–1426, 2010.
- R. K. Kelley and A. H. Ko, “Erlotinib in the treatment of advanced pancreatic cancer,” Biologics, vol. 2, no. 1, pp. 83–95, 2008.
- S. Ueda, S. Ogata, H. Tsuda et al., “The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma,” Pancreas, vol. 29, no. 1, pp. e1–e8, 2004.
- R. Sordella, D. W. Bell, D. A. Haber, and J. Settleman, “Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways,” Science, vol. 305, no. 5687, pp. 1163–1167, 2004.
- S. Tracy, T. Mukohara, M. Hansen, M. Meyerson, B. E. Johnson, and P. A. Jänne, “Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255,” Cancer Research, vol. 64, no. 20, pp. 7241–7244, 2004.
- J. Brognard, A. S. Clark, Y. Ni, and P. A. Dennis, “Akt/pbotein kinace B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation,” Cancer Research, vol. 61, no. 10, pp. 3986–3997, 2001.